GP6

Across TCGA pan-cancer cohorts, GP6 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated GP6 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GP6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GP6 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

STAD, BRCA, and COAD are the cancer types where GP6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.184	0.730	.003	24	view →
BRCA	OS	Median	III,IV	0.211	0.833	<.001	12	view →
COAD	OS	Median	All	0.422	0.874	.005	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
BLCA	DFS	Median	All	1.000	0.330	.044	4	view →
SARC	OS	Median	All	0.134	0.513	.033	3	view →
HNSC	OS	Median	All	0.248	0.661	.042	3	view →
SKCM	DFS	Median	All	0.996	0.715	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

GP6–STAD (OS)

Open the STAD breakdown →